- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03678610
Handling Medium for ICSI With Ionomycin and Latrunculin A
May 5, 2019 updated by: Muhammad Fawzy, Ibn Sina Hospital
Latrunculin A and Ionomycin as a Handling Medium for ICSI
Using Latrunculin A and Ionomycin would improve the outcome of ICSI if the handling medium during the ICSI procedure has them.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
700
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Assiut, Egypt
- Banon Assiut
-
Qena, Egypt, 123456
- Qena Fertility Center
-
Sohag, Egypt
- IbnSina IVF Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 42 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- indication for ICSI
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ICSI medium supplemented with Ionomycin and Latrunculin A
|
Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
|
NO_INTERVENTION: ICSI medium as it is
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fertilization rate
Time Frame: 6 days of culture
|
6 days of culture
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ongoing pregnancy rate
Time Frame: 12 weeks
|
12 weeks
|
|
embryo utilization rate
Time Frame: 6 days of culture
|
6 days of culture
|
|
Rates of Blastocyst formation and quality
Time Frame: 6 days of culture
|
Number of formed blastocysts and blastocysts with good-quality per fertilized oocytes
|
6 days of culture
|
clinical pregnancy rate
Time Frame: three months
|
three months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 25, 2018
Primary Completion (ACTUAL)
May 1, 2019
Study Completion (ACTUAL)
May 1, 2019
Study Registration Dates
First Submitted
September 17, 2018
First Submitted That Met QC Criteria
September 18, 2018
First Posted (ACTUAL)
September 19, 2018
Study Record Updates
Last Update Posted (ACTUAL)
May 7, 2019
Last Update Submitted That Met QC Criteria
May 5, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ibnsina-ICSI-ionomycin-LA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A
-
Ibn Sina HospitalCompleted
-
Ibn Sina HospitalBanoon IVF CenterCompleted
-
Ibn Sina HospitalBanoon IVF Center; Qena Fertility CenterCompleted
-
Lawson Health Research InstituteCompletedBacterial VaginosisTanzania
-
Ibn Sina HospitalCompleted
-
University of AlcalaCompleted
-
South Valley UniversityIbn Sina Hospital; Qena Fertility Center, Qena, EgyptUnknownImprovement of Embryo Transfer Technique | Improvement of Implantation
-
IRCCS San RaffaeleCompleted
-
NestléCompleted
-
Jan JakobssonUniversity of California, IrvineTerminated